Increased awareness in women’s health has taken place over the last 5 to 10 years, especially associated with aging, where perimenopause and menopause have been highlighted topics. This review examines how changes with age in women during perimenopause and menopause lead to estrogen-deficient skin and impaired quality of life (QOL). The topics presented include: (1) the reasons why women’s health (perimenopause and menopause) is finally taking a prominent position in the public and medical mindset, (2) chronological (intrinsic) and photo (extrinsic) skin aging characteristics and skin changes by each decade of life, (3) the importance of and the changes to estrogen levels in aging women (especially with perimenopause and menopause) that lead to estrogen-deficient skin, (4) in brief, hormonal and selective estrogen receptor modulators (SERMs), including polyphenolic and isoflavonoid treatments, plus influencing lifestyle factors, and (5) using skin changes, as the “observable organ” and a reflective mirror of internal aging in women that may signal the potential decline of various unseen tissue/organ systems. This represents a different paradigm for the functional aspects in the body associated with the shifts in and loss of estrogen. Thus, skin health with aging (and the decline in and loss of estrogen) may provide nutritional and medical professionals, especially dermatologists, with a unique position to lead a discussion with patients to consider healthiness beyond dermal changes. Finally, potential treatments to assist and/or enhance women’s healthspan and longevity may be part of this exchange in a collaborative examination. Graphical abstract available for this article.
Psoriasis (PsO) is a chronic inflammatory skin disorder with variable severity. Traditional trial criteria based on Psoriasis Area and Severity Index (PASI) and body surface area (BSA) may not adequately reflect disease burden, particularly in patients with high-impact site involvement (scalp, groin/genitals, hands/feet, armpits). This study aimed to describe treatment outcomes, clinical characteristics, and satisfaction among patients receiving biologics or advanced oral therapies in real-world practice. This cross-sectional analysis used data from the 2024 Psoriasis Wave XI of the Adelphi Real World Disease Specific Programme™ in the USA. Dermatologists completed patient record forms, and patients completed linked patient self-completion questionnaires. Patients were stratified by current treatment (biologics/biosimilars vs. advanced oral therapies) and physician-assessed disease severity (mild vs. moderate-to-severe). Descriptive and bivariate analyses were conducted. Among 682 patients, 466 (68.3
Vitiligo is a chronic autoimmune disease characterized by progressive skin depigmentation. Many patients experience delayed diagnosis, which can prolong associated psychosocial burden. This study explored vitiligo diagnostic and management approaches among healthcare professionals (HCPs) who regularly treat patients with vitiligo. The cross-sectional, multinational Vitiligo and Life Impact Among International Communities (VALIANT) survey recruited HCPs practicing in dermatology, primary medicine, or internal medicine and assessed how they diagnose and treat vitiligo. Among 1203 HCPs who completed the survey, most were dermatologists (91.4
Moderate-to-severe plaque psoriasis is a chronic inflammatory disease linked to significant morbidity and reduced quality of life (QoL). Prospective data on interleukin-23 (IL-23) inhibitors in Indian patients remain limited. This phase III, open-label, multicentre, single-arm bridging study assessed the efficacy, safety and immunogenicity of tildrakizumab 100 mg in Indian patients. Adults with plaque psoriasis for ≥ 6 months, body surface area (BSA) involvement of 10–50
Prospective human evidence for liquid-form polycaprolactone (PCL) in facial rejuvenation is limited. We evaluated skin-quality changes and adverse events following treatment. Thirty participants received three monthly superficial subcutaneous (clinically intended subdermal) treatments in an uncontrolled prospective study. Skin mechanical, pigmentary, hydration, and sebum measurements were assessed through 6 months. The registered Antera primary outcomes are not included in this focused report. Instrumental measurements were also collected at 9 and 12 months but were excluded after calibration-related reliability concerns were identified during review of the late dataset; an institutional review board amendment subsequently restricted instrumental reporting to 6 months. Analyses used mixed-effects models; the corrected analysis of the delayed-to-immediate deformation ratio (R6) used restricted maximum likelihood and Bonferroni-adjusted baseline comparisons. All 30 participants completed treatment; attendance was 29 at 1 month and 28 at 3 and 6 months. Maximum skin deformation (R0) decreased from 0.153 ± 0.062 to 0.112 ± 0.105 mm at 6 months. The delayed-to-immediate deformation ratio (R6) decreased from 0.307 ± 0.307 to 0.174 ± 0.277 (adjusted p = 0.038; overall p = 0.001). Hydration decreased. Bruising, swelling, and persistent postprocedural pain were reported; one swelling event was moderate and the remaining events were mild. All resolved without specific treatment. No serious adverse events were reported in the available safety summary. Skin mechanical changes were observed following liquid-form PCL treatment. The uncontrolled design, variability, and retrospective restriction of instrumental reporting limit conclusions about efficacy, mechanism, and long-term durability. Larger controlled studies are needed. Thai Clinical Trials Registry, TCTR20250209003; retrospectively registered on February 9, 2025. This study explored changes in skin measurements after three monthly injections of liquid-form polycaprolactone in 30 adults. There was no untreated comparison group. Some measures of skin deformation changed after treatment, while skin hydration decreased. Bruising, swelling, and pain after treatment were reported; one swelling event was moderate and the other reported events were mild. They resolved without specific treatment. The study registry also included Antera-based wrinkle and texture outcomes, but this article is a focused report of probe-based skin measurements and safety. Instrumental results are reported only through 6 months because calibration-related reliability concerns were identified after the 9- and 12-month measurements had been collected; the subsequent reporting restriction was approved by the institutional review board. The findings cannot prove that the injections caused the changes or determine how the product acted in the skin. Larger controlled studies are needed.
